19-nordeoxycorticosterone profile

19-nordeoxycorticosterone (19-nor-DOC) is a synthetic steroid hormone that is structurally similar to the naturally occurring hormone deoxycorticosterone (DOC).

**Key differences:**

* **19-nor-DOC lacks the methyl group at the C19 position** present in DOC. This structural modification significantly affects its activity.
* **19-nor-DOC is a potent mineralocorticoid** with high affinity for the mineralocorticoid receptor (MR). In contrast, DOC has both mineralocorticoid and glucocorticoid activity.

**Importance for Research:**

19-nor-DOC has been studied extensively for its potential therapeutic applications and its role in understanding mineralocorticoid receptor signaling. Here are some key areas:

**1. Treatment of Mineralocorticoid Deficiency:**

* 19-nor-DOC's potent mineralocorticoid activity makes it a potential treatment for conditions like Addison's disease, where the adrenal glands produce insufficient aldosterone, a critical mineralocorticoid hormone.

**2. Study of Mineralocorticoid Receptor Signaling:**

* 19-nor-DOC acts as a selective agonist for the MR, enabling researchers to study the specific role of this receptor in various physiological processes. This includes:
* **Blood pressure regulation:** MR activation plays a crucial role in blood pressure homeostasis.
* **Sodium and potassium balance:** Mineralocorticoids regulate electrolyte balance, which is essential for various bodily functions.
* **Cardiovascular health:** MR activation can influence cardiac function and contribute to cardiovascular diseases.

**3. Drug Discovery and Development:**

* Understanding the mechanism of action of 19-nor-DOC can inform the development of new drugs targeting the MR for various medical conditions.

**4. Animal Models:**

* 19-nor-DOC is used to create animal models of mineralocorticoid excess, which allows researchers to study the long-term effects of this hormone on various organs and systems.

**5. Research into other Steroid Hormones:**

* Studies using 19-nor-DOC help researchers understand the structure-activity relationships of other steroid hormones and their interactions with various receptors.

**Overall, 19-nor-DOC serves as a valuable tool for researchers investigating mineralocorticoid receptor signaling, its role in various physiological processes, and its potential therapeutic applications.**

19-nordeoxycorticosterone: isolated from urine of castrated rats with regenerating adrenals [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5069272
MeSH ID	M0071120

Synonym
19-nordeoxycorticosterone
AKOS024342113
4682-70-6

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	35 (76.09)	18.7374
1990's	11 (23.91)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (7.69%)	6.00%
Case Studies	2 (3.85%)	4.05%
Observational	0 (0.00%)	0.25%
Other	46 (88.46%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	1.96	1	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
pargyline Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.	2.89	4	aromatic amine
corticosterone [no description available]	4.67	9	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	3.46	2	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
aldosterone [no description available]	10.59	14	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	4.32	6	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	7.07	46	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
18-hydroxycorticosterone [no description available]	1.97	1	11beta-hydroxy steroid; 18-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo steroid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
formestane [no description available]	1.97	1	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
18-hydroxydeoxycorticosterone 18-hydroxydeoxycorticosterone: structure given in first source	4.32	6	18-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid
tetrahydroaldosterone tetrahydroaldosterone: RN given refers to (3alpha,5beta,11beta)-isomer	1.96	1	steroid lactone
19-noraldosterone [no description available]	1.95	1	21-hydroxy steroid
aldosterone 18-glucuronide [no description available]	1.96	1	steroid glucosiduronic acid
19-hydroxydeoxycorticosterone 19-hydroxydeoxycorticosterone: structure in first source	2.36	2	19-hydroxydeoxycorticosterone; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid
19-norcorticosterone [no description available]	7.65	3
19-oxo-deoxycorticosterone 19-oxo-deoxycorticosterone: metabolite of deoxycorticosterone in rat adrenals	2.38	2	21-hydroxy steroid
cortisone [no description available]	1.97	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
19-norprogesterone 19-norprogesterone: RN given refers to cpd without isomeric designation	6.96	1	corticosteroid hormone
19-hydroxy-4-androstene-3,17-dione [no description available]	3.06	1	17-oxo steroid; 19-hydroxy steroid; 3-oxo steroid; androstanoid	mouse metabolite
plomestane plomestane: selective inhibitor of aromatization in human breast tissue; may provide a mechanism for controlling estrogen responsive processes	2.89	4
18-hydroxycortisol 18-hydroxycortisol: from urine of patients with primary aldosteronism. 18-hydroxycortisol : A 18-hydroxy steroid that is cortisol carrying a hydroxy group at position 18. Its urinary excretion is increased in patients with aldosterone-producing adenoma.	1.97	1
18-oxocortisol 18-oxocortisol: biosynthesized by aldosterone-producing adrenal tissue; structure given in first source. 18-oxocortisol : A steroid aldehyde that is cortisol carrying a formyl group at position 18.	1.97	1

Condition	Relationship Strength	Studies
Blood Pressure, High [description not available]	5.13	18
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	5.13	18
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	1.96	1
Inappropriate GH Secretion Syndrome (Acromegaly) [description not available]	1.96	1
Aldosteronism [description not available]	7.88	4
Cancer of Pituitary [description not available]	1.96	1
Adrenal Cortex Cancer [description not available]	1.96	1
Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)	1.96	1
Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX.	1.96	1
Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.	2.88	4
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	1.96	1
Congenital Adrenal Hyperplasia [description not available]	2.65	3
Hypergonadotropic Hypogonadism [description not available]	1.96	1
Adrenal Hyperplasia, Congenital A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.	2.65	3
Hypogonadism Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).	1.96	1
Adenoma, Basal Cell [description not available]	2.38	2
Adrenal Cancer [description not available]	2.38	2
Adenoma A benign epithelial tumor with a glandular organization.	2.38	2
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.38	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	8.29	2
Cyst [description not available]	6.97	1
Adrenal Gland Diseases Pathological processes of the ADRENAL GLANDS.	1.97	1
Cardiovascular Pregnancy Complications [description not available]	1.97	1
Eclampsia Onset of HYPERREFLEXIA; SEIZURES; or COMA in a previously diagnosed pre-eclamptic patient (PRE-ECLAMPSIA).	1.97	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.97	1
Diathesis [description not available]	1.96	1

19-nordeoxycorticosterone

Description

Cross-References

Synonyms (3)

Research

Studies (46)

Study Types